TY - JOUR
T1 - Cancer genomic medicine in Japan and the roles of pharmacists
AU - Aomori, Tohru
AU - Sakurai, Hiroomi
AU - Nishihara, Hiroshi
N1 - Publisher Copyright:
© 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/8/1
Y1 - 2022/8/1
N2 - Cancer genomic medicine (CGM) is a medical service that provides optimized treatment for each patient based on genes, biomarkers, environment, and lifestyle. In Japan, the approval of designed core hospitals for CGM started in 2017. In June 2019, two types of cancer gene panel tests became available in the national health insurance system, and CGM was socially implemented. While CGM is still in its infancy and there are some issues that need to be resolved, there are cases where the treatment has shown dramatic results. The present review highlights the CGM system in Japan, the issues it faces, and the role of pharmacists in this system.
AB - Cancer genomic medicine (CGM) is a medical service that provides optimized treatment for each patient based on genes, biomarkers, environment, and lifestyle. In Japan, the approval of designed core hospitals for CGM started in 2017. In June 2019, two types of cancer gene panel tests became available in the national health insurance system, and CGM was socially implemented. While CGM is still in its infancy and there are some issues that need to be resolved, there are cases where the treatment has shown dramatic results. The present review highlights the CGM system in Japan, the issues it faces, and the role of pharmacists in this system.
KW - cancer genomic medicine
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85134721298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134721298&partnerID=8YFLogxK
U2 - 10.1097/FPC.0000000000000476
DO - 10.1097/FPC.0000000000000476
M3 - Review article
C2 - 35696282
AN - SCOPUS:85134721298
SN - 1744-6872
VL - 32
SP - 242
EP - 245
JO - Pharmacogenetics and Genomics
JF - Pharmacogenetics and Genomics
IS - 6
ER -
